Bayesian meta-analysis of 10 RCTs (6515 adults with overweight or obesity): tirzepatide vs placebo was not significantly associated with atrial fibrillation (OR 2.20, 95% CrI 0.81–6.75); odds of any arrhythmia were higher (OR 1.84, 1.04–3.90) but events were rare.
Meta-analysisn = 6,515
Mansouri et al. Tirzepatide and the Incidence of Atrial Fibrillation in Adults With Overweight or Obesity: An Updated Meta-Analysis of Randomized Controlled Trials